| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
AGIO
Agios Pharma
|
Sep 21, 2026 | BUY |
Strong Buy
+87.8% avg upside
29 analysts
|
$50.00
48.50% Upside
|
-1.6% | · |
|
CADL
Candel Therapeutics
|
Sep 21, 2026 | BUY |
Strong Buy
+82.8% avg upside
11 analysts
|
$18.00
69.50% Upside
|
-2.9% | · |
|
RXRX
Recursion Pharmaceuticals
|
Sep 21, 2026 | HOLD |
Buy
+91.8% avg upside
12 analysts
|
— | -6.8% | · |
|
RVMD
Revolution Medicines
|
Sep 21, 2026 | BUY |
Strong Buy
-0.1% avg upside
34 analysts
|
$265.00
27.51% Upside
|
+5.9% | · |
|
KRYS
Krystal Biotech
|
Sep 21, 2026 | BUY |
Strong Buy
-15.5% avg upside
20 analysts
|
$400.00
19.31% Upside
|
+3.6% | · |
|
HCM
HUTCHMED
|
Sep 21, 2026 | BUY |
Strong Buy
+111.2% avg upside
9 analysts
|
$18.00
22.13% Upside
|
-2.4% | · |
|
RGNX
RegenXBio
|
Sep 21, 2026 | BUY |
Strong Buy
+400.3% avg upside
22 analysts
|
$15.00
95.96% Upside
|
-6.1% | · |
|
XNCR
Xencor
|
Sep 21, 2026 | HOLD |
Strong Buy
+43.3% avg upside
27 analysts
|
$26.00
1.13% Upside
|
+2.3% | · |
|
MRNA
Moderna
|
Sep 18, 2026 | HOLD |
Hold
-45.7% avg upside
38 analysts
|
$170.00
10.44% Downside
|
+24.1% | · |
|
NVAX
Novavax
|
Sep 18, 2026 | SELL |
Hold
+114.4% avg upside
20 analysts
|
$7.00
36.05% Downside
|
-6.4% | · |
|
PRQR
ProQR
|
Sep 10, 2026 | BUY |
Strong Buy
+573.7% avg upside
19 analysts
|
$8.00
381.94% Upside
|
-14.9% | · |
|
BEAM
Beam Therapeutics
|
Sep 08, 2026 | BUY |
Strong Buy
+112.2% avg upside
25 analysts
|
$43.00
74.26% Upside
|
-8.5% | · |
|
ERAS
Erasca
|
Aug 26, 2026 | HOLD |
Strong Buy
+43.4% avg upside
14 analysts
|
$20.00
37.09% Upside
|
-23.9% | · |
|
IMTX
Immatics
|
Aug 18, 2026 | BUY |
Strong Buy
+108.9% avg upside
15 analysts
|
$17.00
92.30% Upside
|
-7.9% | · |
|
SANA
Sana Biotechnology
|
Aug 14, 2026 | BUY |
Strong Buy
+235.6% avg upside
14 analysts
|
$6.00
104.48% Upside
|
-18.0% | · |
|
CATX
Perspective Therapeutics
|
Aug 14, 2026 | HOLD |
Strong Buy
+306.1% avg upside
24 analysts
|
$5.00
88.03% Upside
|
-21.2% | · |
|
MGTX
Meiragtx Holdings
|
Aug 14, 2026 | BUY |
Strong Buy
+131.0% avg upside
14 analysts
|
$19.00
70.19% Upside
|
-18.6% | · |
|
CRBU
Caribou Biosciences
|
Aug 14, 2026 | BUY |
Strong Buy
+783.3% avg upside
12 analysts
|
$5.00
295.20% Upside
|
-21.5% | · |
|
AKTS
Aktis Oncology, Inc.
|
Aug 14, 2026 | BUY |
Strong Buy
+70.7% avg upside
12 analysts
|
$34.00
74.53% Upside
|
-21.9% | · |
|
WVE
Wave Life Sciences
|
Aug 12, 2026 | BUY |
Strong Buy
+453.3% avg upside
29 analysts
|
$17.00
360.79% Upside
|
-27.9% | · |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+21.2% avg upside
17 analysts
|
$88.00
21.54% Upside
|
-7.3% | · |
|
JANX
Janux Therapeutics Inc
|
Aug 07, 2026 | BUY |
Strong Buy
+163.5% avg upside
22 analysts
|
$22.00
26.32% Upside
|
+4.6% | · |
|
VIR
Vir Biotechnology
|
Aug 07, 2026 | BUY |
Strong Buy
+128.3% avg upside
16 analysts
|
$15.00
35.32% Upside
|
+20.9% | · |
|
ALEC
Alector
|
Aug 07, 2026 | SELL |
Buy
+437.1% avg upside
15 analysts
|
$1.00
46.74% Downside
|
-7.9% | · |
|
AVTX
Avalo Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+248.5% avg upside
20 analysts
|
$35.00
126.27% Upside
|
-17.7% | · |
|
EDIT
Editas Medicine
|
Aug 07, 2026 | SELL |
Buy
+417.0% avg upside
33 analysts
|
— | +10.8% | · |
|
NTLA
Intellia Therapeutics
|
Aug 07, 2026 | HOLD |
Buy
+209.2% avg upside
37 analysts
|
$17.00
41.72% Upside
|
+1.0% | · |
|
CRSP
Crispr Therapeutics AG
|
Aug 05, 2026 | BUY |
Buy
+36.3% avg upside
41 analysts
|
$82.00
45.98% Upside
|
+5.5% | · |
|
TGTX
TG Therapeutics
|
Aug 05, 2026 | SELL |
Strong Buy
-19.5% avg upside
20 analysts
|
$21.00
62.90% Downside
|
-12.7% | · |
|
BTAIQ
Bioxcel Therapeutics
|
Mar 27, 2026 | SELL |
Strong Buy
+49171.2% avg upside
12 analysts
|
$1.00
2122.26% Upside
|
· | · |
|
REGN
Regeneron
|
Dec 10, 2024 | SELL |
Strong Buy
+5.4% avg upside
59 analysts
|
$565.00
24.93% Downside
|
+6.2% | · |
|
LLY
Eli Lilly & Co
|
Nov 01, 2024 | BUY |
Strong Buy
-6.8% avg upside
49 analysts
|
$1100.00
7.33% Downside
|
+6.2% | · |
|
DMRA
Damora Therapeutics
|
Aug 15, 2023 | BUY |
Strong Buy
+43.4% avg upside
20 analysts
|
$5.00
76.74% Downside
|
-16.5% | · |
|
NXTC
NextCure
|
Dec 02, 2022 | SELL |
Buy
+255.1% avg upside
10 analysts
|
$1.00
79.81% Downside
|
+14.9% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.